Navigation Links
Sagent Pharmaceuticals Launches Cefazolin for Injection, USP
Date:3/13/2008

certain surgical infections. The most common adverse effects may include mild nausea, diarrhea, oral candidiasis and pain or tenderness at the injection site. Less common adverse effects include vomiting, and rarely, pseudomembranous colitis.

About Sagent Pharmaceuticals, Inc.

Sagent Pharmaceuticals, founded in 2006, is a privately held specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectable products. Sagent has created a unique, global network of resources, comprised of rapid development capabilities, sophisticated manufacturing and innovative drug-delivery technologies, quickly yielding an extensive portfolio of pharmaceutical products that fulfills the evolving needs of patients. Sagent currently has more than 200 products in development.

To Discover Injectables Excellence(TM) and learn more about Sagent, please visit http://www.SagentPharma.com.


'/>"/>
SOURCE Sagent Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Anesiva Signs Co-Promotion and Distribution Agreement With Sagent Pharmaceuticals for Zingo(TM) in U.S. Hospitals
2. Sagent Pharmaceuticals, Inc. to Present at Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
3. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
4. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
7. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
8. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
9. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
10. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
11. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... - Results From a Survey Conducted by ... Major Industrialized Countries , , - A ... impacts their enjoyment of the ... arthritis find shopping for gifts, ... difficult to do, ...
(Date:12/11/2009)... Dec. 11 Dendreon Corporation (Nasdaq: ... its previously announced public offering have exercised in ... shares of common stock at the public offering ... of the option increases the size of the ... common stock. Dendreon expects to receive net ...
(Date:12/11/2009)... 2009 -- Researchers have discovered a new explanation for differences ... excess copies of a certain gene, the more serious the ... it is suspected that it is the amount of copies ... being published in the American Journal of Human Genetics ... of Guy Froyen connected to VIB, a life sciences research ...
(Date:12/11/2009)... Corporation announced today the enrollment and dosing at the ... the first patient in the ACE ( AC ... 2 pivotal trial in patients with relapsed or refractory ... orally available, potent and highly selective small molecule that ... inhibitor. The ACE study is designed to be ...
Breaking Biology Technology:Rheumatoid Arthritis Patients Want Pain-Free Days at Christmas 2Rheumatoid Arthritis Patients Want Pain-Free Days at Christmas 3Rheumatoid Arthritis Patients Want Pain-Free Days at Christmas 4Dendreon Announces Exercise of Option by Underwriters in its Common Stock Offering 2Dendreon Announces Exercise of Option by Underwriters in its Common Stock Offering 3Amount of gene surplus determines severity of mental retardation in males 2Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 2Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 3Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 4Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 5
... NimbleGen , a Madison biotech firm that ... 2003 Severe Acute Respiratory Syndrome outbreak in Singapore has won ... a total of $41 million since its inception in 2000. ... will continue to pursue market opportunities in micro-array technology. He ...
... What does it mean to the biotech community ... question should be thoroughly addressed at the Wisconsin Life ... Where Science Spawns Novel Therapies. The conference will be held ... a biotechnology showcase about 20 companies, 11 from Wisconsin, ...
... Madison, Wis. The University of Wisconsin-Madison plans to ... by June 2006, according to the Division of Information ... that 46 percent of students said they were likely to ... across the campus, DoIT announced on November 2 that it ...
Other Biology Technology:Wisconsin company with SARS diagnostic role lands $13 million investment 2Life-sciences conference to feature novel research with clinical potential 2UW-Madison working to extend wireless access to entire campus 2
(Date:12/13/2009)... The Scripps Research Institute have solved a 10-year-old ... ancient family of enzymes can have two completely ... providing guidance for understanding other molecules in the ... the protein,s possible use for combating diseases including ... published in the December 13, 2009 advance, online ...
(Date:12/11/2009)... collectively weigh and initiate different survival strategies say they ... decisions that affect their health, wealth and the fate ... week in the early online edition of the journal ... was accomplished when the scientists applied the mathematical techniques ... genes and proteins that colonies of bacteria rely upon ...
(Date:12/11/2009)... the deep ocean,s temperature variability and circulation system could ... deep ocean is affected more by surface warming than ... predictions of factors such as sea level rise and ... also been found to result in a more vigorous ... faster transport of large quantities of warm water, with ...
Breaking Biology News(10 mins):Scripps Research scientists crack mystery of protein's dual function 2Scripps Research scientists crack mystery of protein's dual function 3Bacteria provide new insights into human decision making 2Bacteria provide new insights into human decision making 3Bacteria provide new insights into human decision making 4Bacteria provide new insights into human decision making 5New discoveries could improve climate projections 2Long Term Data Updates Show Further Extensions of Survival and Delays in Recurrence in Brain Cancer Patients Who Received DCVax 28R 29 Brain 5631 1Long Term Data Updates Show Further Extensions of Survival and Delays in Recurrence in Brain Cancer Patients Who Received DCVax 28R 29 Brain 5631 2Long Term Data Updates Show Further Extensions of Survival and Delays in Recurrence in Brain Cancer Patients Who Received DCVax 28R 29 Brain 5631 3Long Term Data Updates Show Further Extensions of Survival and Delays in Recurrence in Brain Cancer Patients Who Received DCVax 28R 29 Brain 5631 4Long Term Data Updates Show Further Extensions of Survival and Delays in Recurrence in Brain Cancer Patients Who Received DCVax 28R 29 Brain 5631 5Shire Targets Fourth Quarter Filing of BLA for REPLAGAL 28R 29 for Fabry Disease With U S FDA 5629 1Shire Targets Fourth Quarter Filing of BLA for REPLAGAL 28R 29 for Fabry Disease With U S FDA 5629 2Shire Targets Fourth Quarter Filing of BLA for REPLAGAL 28R 29 for Fabry Disease With U S FDA 5629 3Shire Targets Fourth Quarter Filing of BLA for REPLAGAL 28R 29 for Fabry Disease With U S FDA 5629 4Vestara Joins National Health Organization Practice Greenhealth to Further Support Environmental Practices 59887 1Vestara Joins National Health Organization Practice Greenhealth to Further Support Environmental Practices 59887 2Vestara Joins National Health Organization Practice Greenhealth to Further Support Environmental Practices 59887 3
... key role in a new federal effort to significantly ... with solid surfaces basic studies that have potential ... for converting solar and electrical energy into fuel, improved ... That is the focus of a new multi-million-dollar Energy ...
... be home to a new Energy Frontier Research Center (EFRC) ... delivered by President Barack Obama. , The ASU center, ... on solar energy conversion based on the principles of photosynthesis, ... to useful energy. All 46 centers and are being established ...
... very small differences in people,s genes, scientists from Cornell ... events in human history and pinpointing the origins of ... issue of the journal GENETICS ( http://www.genetics.org ... population moved close to extinction and helps scientists close ...
Other Biology News:Vanderbilt engineers play key role in new DOE energy frontier research center 2DOE funds bio-inspired solar fuel center at Arizona State 2DOE funds bio-inspired solar fuel center at Arizona State 3DOE funds bio-inspired solar fuel center at Arizona State 4Tiny differences in our genes help shed light on the big picture of human history 2
Recognizes Human Connexin 45. Due to sequence homologies, this antibody is also expected to react with canine (100% homology) and mouse (92% homology) Connexin 45. Also confirmed to work on rat C6 c...
... BCIP/NBT Chromogen system consists of ... in a single component,solution. The ... the presence of alkaline phosphatase ... minimal background noise. ,The System ...
...
... is primarily used for the preparation of ... for tracing. NH2-Reactive B-Phycoerythrin, a component of ... can easily make a covalent bond with ... without any activation process. Filtration Tube included ...
Biology Products: